By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Nimbus Therapeutics 

25 First Street
Suite 404
Cambridge  Massachusetts  02141  U.S.A.
Phone: 857-999-2009 Fax: 617-231-0652



Company News
Nimbus Therapeutics Enters Into Strategic Partnership With Charles River  (CRL) To Advance New Therapeutic Programs 4/5/2017 7:47:56 AM
Nimbus Therapeutics Appoints Mark Ashwell, Ph.D., As Head Of Chemistry 1/5/2017 11:21:49 AM
Nimbus Therapeutics Announces $200 Million Milestone Payment From Gilead (GILD) For Allosteric ACC Inhibitor Program In Non-alcoholic Steatohepatitis (NASH) 11/2/2016 9:12:53 AM
Nimbus Therapeutics Announces Closing Of Gilead (GILD)’ Acquisition Of Nimbus Apollo, Inc., And Its Acetyl-CoA Carboxylase (ACC) Inhibitor Program 5/17/2016 11:09:22 AM
Nimbus Therapeutics Granted Fast Track Designation For Its Allosteric ACC Inhibitor, NDI-010976, For The Treatment Of NASH 2/2/2016 9:53:28 AM
Nimbus Therapeutics Achieves Second Milestone In Research Collaboration With Monsanto  (MON) 12/23/2015 12:51:58 PM
Nimbus Therapeutics Announces Progress On Key Therapeutic Programs 11/10/2015 12:58:23 PM
Nimbus Therapeutics Scores a Global License Agreement with Genentech (RHHBY), Financial Terms Undisclosed 10/20/2015 6:16:12 AM
Nimbus Therapeutics Appoints Annie C. Chen, M.D., M.P.H., As Chief Medical Officer 9/9/2015 10:52:27 AM
Nimbus Therapeutics Appoints Mark Iwicki And George Vlasuk To Its Board Of Directors 7/7/2015 10:14:41 AM